These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 6491278)
21. The ovine nasal mucosa: an alternative tissue site for mucosal immunization. Sedgmen BJ; Lofthouse SA; Meeusen EN Methods; 2006 Feb; 38(2):112-6. PubMed ID: 16427306 [TBL] [Abstract][Full Text] [Related]
22. Effects of parenteral keyhole limpet hemocyanin or cholera toxin on intestinal immune response to keyhole limpet hemocyanin. Hamilton SR; Keren DF; Yardley JH; Brown G Int Arch Allergy Appl Immunol; 1982; 68(3):242-6. PubMed ID: 7085119 [TBL] [Abstract][Full Text] [Related]
23. Genetic control of the murine immune response to cholera toxin. Elson CO; Ealding W J Immunol; 1985 Aug; 135(2):930-2. PubMed ID: 3925014 [TBL] [Abstract][Full Text] [Related]
24. IL-6-deficient mice exhibit normal mucosal IgA responses to local immunizations and Helicobacter felis infection. Bromander AK; Ekman L; Kopf M; Nedrud JG; Lycke NY J Immunol; 1996 Jun; 156(11):4290-7. PubMed ID: 8666800 [TBL] [Abstract][Full Text] [Related]
25. Morphologic and functional alterations of mucosal T cells by cholera toxin and its B subunit. Elson CO; Holland SP; Dertzbaugh MT; Cuff CF; Anderson AO J Immunol; 1995 Feb; 154(3):1032-40. PubMed ID: 7822780 [TBL] [Abstract][Full Text] [Related]
26. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant. Holmgren J; Czerkinsky C; Lycke N; Svennerholm AM Am J Trop Med Hyg; 1994; 50(5 Suppl):42-54. PubMed ID: 8203723 [TBL] [Abstract][Full Text] [Related]
27. Involvement of antigen-presenting cells in the enhancement of the in vitro antibody responses by cholera toxin B subunit. Hirabayashi Y; Tamura SI; Shimada K; Kurata T Immunology; 1992 Mar; 75(3):493-8. PubMed ID: 1374056 [TBL] [Abstract][Full Text] [Related]
28. Cholera toxin and cholera toxin B subunit induce IgA switching through the action of TGF-beta 1. Kim PH; Eckmann L; Lee WJ; Han W; Kagnoff MF J Immunol; 1998 Feb; 160(3):1198-203. PubMed ID: 9570534 [TBL] [Abstract][Full Text] [Related]
29. Transcutaneous immunization with phosphorylcholine induces antigen-specific mucosal and systemic immune responses in BALB/c mice. Nagano H; Kurono Y Auris Nasus Larynx; 2015 Dec; 42(6):478-82. PubMed ID: 26092312 [TBL] [Abstract][Full Text] [Related]
30. Oral tolerance in humans: failure to suppress an existing immune response by oral antigen administration. Moldoveanu Z; Oliver F; Mestecky J; Elson CO Ann N Y Acad Sci; 2004 Dec; 1029():299-309. PubMed ID: 15681767 [TBL] [Abstract][Full Text] [Related]
31. Murine immune responses to Salmonella lipopolysaccharide: oral administration of whole bacteria to C3H/HeJ mice induces secondary anti-LPS responses, especially of the IgA isotype. Jirillo E; Kiyono H; Michalek SM; McGhee JR J Immunol; 1984 Apr; 132(4):1702-11. PubMed ID: 6366051 [TBL] [Abstract][Full Text] [Related]
32. Immune responses of mice to orally administered asialo GM1-specific rabbit IgG in the presence or absence of cholera toxin. Umesaki Y; Setoyama H Immunology; 1992 Feb; 75(2):386-8. PubMed ID: 1551702 [TBL] [Abstract][Full Text] [Related]
33. Keyhole limpet hemocyanin-propagated Peyer's patch T cell clones that help IgA responses. Maghazachi AA; Phillips-Quagliata JM J Immunol; 1988 May; 140(10):3380-8. PubMed ID: 3283231 [TBL] [Abstract][Full Text] [Related]
34. Strong mucosal adjuvanticity of cholera toxin within lipid particles of a new multiple emulsion delivery system for oral immunization. Tomasi M; Dertzbaugh MT; Hearn T; Hunter RL; Elson CO Eur J Immunol; 1997 Oct; 27(10):2720-5. PubMed ID: 9368632 [TBL] [Abstract][Full Text] [Related]
35. Parenteral immunization causes antigen-specific cell-mediated suppression of an intestinal IgA response. Koster FT; Pierce NF J Immunol; 1983 Jul; 131(1):115-9. PubMed ID: 6190901 [TBL] [Abstract][Full Text] [Related]
36. Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant. Castagliuolo I; Sardina M; Brun P; DeRos C; Mastrotto C; Lovato L; Palù G Infect Immun; 2004 May; 72(5):2827-36. PubMed ID: 15102793 [TBL] [Abstract][Full Text] [Related]
37. Cholera toxin as a mucosal adjuvant: III. Antibody responses to nontarget dietary antigens are not increased. Nedrud JG; Sigmund N Reg Immunol; 1990-1991; 3(5):217-22. PubMed ID: 1966580 [TBL] [Abstract][Full Text] [Related]
38. Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus. Liang XP; Lamm ME; Nedrud JG J Immunol; 1988 Sep; 141(5):1495-501. PubMed ID: 2842395 [TBL] [Abstract][Full Text] [Related]
39. Cholera toxin increases T lymphocyte responses to unrelated antigens. Hornquist E; Lycke N Adv Exp Med Biol; 1995; 371B():1507-12. PubMed ID: 7502846 [TBL] [Abstract][Full Text] [Related]
40. Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Jackson RJ; Fujihashi K; Xu-Amano J; Kiyono H; Elson CO; McGhee JR Infect Immun; 1993 Oct; 61(10):4272-9. PubMed ID: 8406816 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]